SLAMF7 Targeted Therapies
1 drugsAbout SLAMF7
SLAMF7 (CD319 or CRACC) is a cell surface receptor in the SLAM family expressed on immune and malignant cells. It modulates immune responses and tumor cell behavior, making it a target in oncology.
Currently, there is no genetic evidence directly linking SLAMF7 to specific diseases. However, its role in modulating immune responses and tumor cell behavior supports therapeutic intervention.
SLAMF7 is targeted by one FDA-approved antibody drug, EMPLICITI (elotuzumab), developed by Bristol-Myers Squibb for oncology indications. EMPLICITI was first approved in 2015.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Relapsed Refractory Multiple Myeloma (RRMM) with only 1 trials.
- phase2 represents biological uncertainty with 47% completion.
Top SLAMF7 Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting SLAMF7.
The market is highly concentrated, suggesting high barriers to entry or untapped potential for new players.
SLAMF7 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SLAMF7, using antibody modality.
Exploring alternative modalities like small molecules or cell therapies could provide a competitive advantage.
SLAMF7 Clinical Trials 62 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 5 | 4 | 6 | 56% |
| Phase 2 | 32 | 17 | 10 | 5 | 63% |
| Phase 3 | 15 | 4 | 3 | 8 | 57% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved SLAMF7 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SLAMF7. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
SLAMF7 Drug Approval Timeline (2015 - 2015)
The first and only drug targeting SLAMF7, EMPLICITI, was approved in 2015.
The approval timeline suggests a potentially unsaturated market with room for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 55 clinical trials targeting SLAMF7.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities